Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population

@article{Bisset2005PerflubronAA,
  title={Perflubron as a gastrointestinal MR imaging contrast agent in the pediatric population},
  author={George S. Iii Bisset and Kathleen H. Emery and Manuel P. Meza and Nancy K. Rollins and Steven Don and Jolene S. Shorr},
  journal={Pediatric Radiology},
  year={2005},
  volume={26},
  pages={409-415}
}
Objective. To evaluate the safety and efficacy of orally administered perflubron for bowel recognition on MR imaging in a pediatric population.Materials and methods. A multicenter trial evaluated 39 pediatric subjects before and after ingestion of perflubron with T1−, proton-density, and T2-weighted sequences through the abdomen and/or pelvis. Post-contrast images were compared with pre-contrast images. Safety was evaluated through assessment of adverse events, clinical laboratory parameters… 

Role of Contrast in MR Imaging

Magnetic resonance imaging now has the potential of being used to monitor enzymatic activity, gene expression, metal ion homeostasis, and cell death in vivo, expanding the current clinical applications of MR contrast media.

Perfluorocarbon Emulsion Contrast Agents: A Mini Review

This mini review aims to discuss the chemistry and physics of perfluorocarbon emulsions, in addition to highlighting some of the past, recent, and potential applications.

Role of MR imaging in pediatric surgery

In this article the authors provide an update on this exciting modality with stress on applications relevant to pediatric surgeons.

VatuximabTM: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

Magnetic resonance imaging allows us to follow the induction and development of tumor vascular damage providing new insight into spatial and temporal activity and facilitating effective combination with the hypoxic cell selective cytotoxin tirapazamine.

Breast Cancer Gene Therapy: Development of Novel Non-Invasive Magnetic Resonance Assay to Optimize Efficacy

This work designed, evaluated and tested a novel approach to gene activity detection- specifically, using fluorinated substrates of beta-galactosidase to reveal gene activity.

(19)F magnetic resonance imaging (MRI): from design of materials to clinical applications.

Clinical Applications Ilaria Tirotta,†,‡ Valentina Dichiarante,†,‡ Claudia Pigliacelli,†,‡ Gabriella Cavallo,†,‡ Giancarlo Terraneo,†,‡ Francesca Baldelli Bombelli,*,†,‡,§ Pierangelo

Possible role of contrast media in reactivation of latent infection

It is proposed that radiological contrast media may disrupt these biofilms, thus enabling the successful treatment of chronic diseases using antibiotics and making it susceptible to the immune system.

Degassed liquids to prevent/treat decompression sickness.

It is hypothesized that administration of degassed liquids will prevent or reverse mild-moderate DCS by increasing the volume of distribution of dissolved gas in DCS victims, and degassed liquid administration should prove to be even more effective adjunct therapy for severe DCS than present gas-saturated liquids.

Degassed liquids to prevent/treat decompression sickness.

References

SHOWING 1-10 OF 24 REFERENCES

Perflubron as an oral contrast agent for MR imaging: results of a phase III clinical trial.

Perflubron is safe, and its efficacy was unaffected by pulse sequences, magnetic field strength, or time delay, in a multicenter trial of magnetic resonance imaging in the abdomen and pelvis.

Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon.

The utility of perfluoroctylbromide (PFOB) as a gastrointestinal contrast agent for magnetic resonance (MR) imaging was evaluated with MR examinations performed in 30 subjects and the severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.

Intraluminal contrast enhancement and MR visualization of the bowel wall: Efficacy of PFOB

While lumen identification is improved with PFOB, its greatest clinical utility may be in facilitating intestinal wall visualization, the authors conclude.

Positive bowel contrast agent for MR imaging of the abdomen: phase II and III clinical trials.

The contrast agent provided new or additional radiologic information in 142 patients, specific additional information in a detected abnormality in 46 of 142 patients (32%), and information that changed diagnosis, management, or surgical approach in 22 of 142 Patients (15%).

Intraluminal contrast agents for MR imaging of the abdomen and pelvis

Compared with precontrast images, MR images acquired after administration of GI contrast agents have shown increased anatomic delineation of the bowel lumen, pancreas, and paraaortic nodes, allowing increased detection of pancreatic lesions, improved assessment of bowel wall lesions, and distinction between intra hepatic and extrahepatic lesions.

First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging.

Use of this contrast agent improved the diagnostic quality of abdominal MR images by enabling the distinction of the bowel from nonbowel structures at concentrations that did not produce image distortion.

Perfluorochemicals as gastrointestinal contrast agents for MR imaging: preliminary studies in rats and humans.

The results suggest that perfluorochemicals have potential as oral contrast agents for MR imaging, and both compounds created signal void in the bowel of both rats and human subjects allowing identification of the gastrointestinal tract.

Gadopentetate dimeglumine as a bowel contrast agent: safety and efficacy.

Gadopentetate dimeglumine is a safe and effective bowel contrast agent for MR imaging and effectively eliminated "ghost" images of the opacified bowel in 105 of 109 cases.

Abdominal MRI using a negative contrast agent.

The diagnostic information was greatly improved after OMP ingestion, and the diagnosis would not have been possible without the use of the contrast agent in 41% of the examinations.